NASDAQ: TRVI
Trevi Therapeutics Inc Stock

$13.35-0.37 (-2.7%)
Updated Nov 20, 2026
TRVI Price
$13.35
Fair Value Price
$0.13
Market Cap
$1.90B
52 Week Low
$9.82
52 Week High
$20.15
P/E
-34.23x
P/B
6.29x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$60.76M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$61M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TRVI Overview

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TRVI's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
TRVI
Ranked
#374 of 447

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important TRVI news, forecast changes, insider trades & much more!

TRVI News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRVI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TRVI ($13.35) is overvalued by 10,566.55% relative to our estimate of its Fair Value price of $0.13 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TRVI ($13.35) is not significantly undervalued (10,566.55%) relative to our estimate of its Fair Value price of $0.13 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TRVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TRVI due diligence checks available for Premium users.

Valuation

TRVI fair value

Fair Value of TRVI stock based on Discounted Cash Flow (DCF)

Price
$13.35
Fair Value
$0.13
Overvalued by
10,566.55%
TRVI ($13.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TRVI ($13.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TRVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TRVI price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-34.23x
Industry
16.91x
Market
39.45x

TRVI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
6.29x
Industry
4.78x
TRVI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TRVI's financial health

Profit margin

Revenue
$0.0
Net Income
-$21.5M
Profit Margin
0%
TRVI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$310.8M
Liabilities
$8.1M
Debt to equity
0.03
TRVI's short-term assets ($305.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRVI's short-term assets ($305.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRVI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TRVI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$19.7M
Investing
-$7.2M
Financing
$412.0k
TRVI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TRVI vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TRVID$1.90B-2.70%-34.23x6.29x
HRMYC$1.91B-1.18%10.55x1.78x
BHVND$1.87B-9.23%-3.29x-19.05x
BCRXC$1.86B-1.37%-5.35x-4.67x
IMNMF$1.85B-5.54%-5.94x4.08x

Trevi Therapeutics Stock FAQ

What is Trevi Therapeutics's quote symbol?

(NASDAQ: TRVI) Trevi Therapeutics trades on the NASDAQ under the ticker symbol TRVI. Trevi Therapeutics stock quotes can also be displayed as NASDAQ: TRVI.

If you're new to stock investing, here's how to buy Trevi Therapeutics stock.

What is the 52 week high and low for Trevi Therapeutics (NASDAQ: TRVI)?

(NASDAQ: TRVI) Trevi Therapeutics's 52-week high was $20.15, and its 52-week low was $9.82. It is currently -33.75% from its 52-week high and 35.95% from its 52-week low.

How much is Trevi Therapeutics stock worth today?

(NASDAQ: TRVI) Trevi Therapeutics currently has 142,559,400 outstanding shares. With Trevi Therapeutics stock trading at $13.35 per share, the total value of Trevi Therapeutics stock (market capitalization) is $1.90B.

Trevi Therapeutics stock was originally listed at a price of $7.89 in May 7, 2019. If you had invested in Trevi Therapeutics stock at $7.89, your return over the last 7 years would have been 69.2%, for an annualized return of 7.8% (not including any dividends or dividend reinvestments).

How much is Trevi Therapeutics's stock price per share?

(NASDAQ: TRVI) Trevi Therapeutics stock price per share is $13.35 today (as of Nov 20, 2026).

What is Trevi Therapeutics's Market Cap?

(NASDAQ: TRVI) Trevi Therapeutics's market cap is $1.90B, as of Nov 21, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Trevi Therapeutics's market cap is calculated by multiplying TRVI's current stock price of $13.35 by TRVI's total outstanding shares of 142,559,400.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.